3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
118
Lung Neoplasms
51
Triple Negative Breast Neoplasms
35
Breast Neoplasms
33
Small Cell Lung Carcinoma
27
Squamous Cell Carcinoma of Head and Neck
25
Ovarian Neoplasms
24
Fallopian Tube Neoplasms
20
Neoplasm Metastasis
19
Neoplasms
16
Parkinson Disease 4, Autosomal Dominant Lewy Body
15
Endometrial Neoplasms
15
Head and Neck Neoplasms
14
Colorectal Neoplasms
10
Carcinoma
10
Prostatic Neoplasms
9
Oropharyngeal Neoplasms
9
Carcinoma, Transitional Cell
9
Urinary Bladder Neoplasms
7
Esophageal Neoplasms
7
Carcinoma, Squamous Cell
7
Pancreatic Neoplasms
6
Lung Diseases
6
Laryngeal Neoplasms
6
Carcinoma, Ovarian Epithelial
6
Uterine Cervical Neoplasms
5
Respiratory Tract Neoplasms
5
Mouth Neoplasms
5
Mesothelioma
5
Carcinoma, Bronchogenic
5
Interventions
pembrolizumab
1
Pemetrexed
1
Control Groups
1
Cisplatin
1
Carboplatin
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Processes
×
Carboplatin
×
90 days
×
Clear all
NCT06119581
2026-05-19
SUNRAY-01
Eli Lilly and Company
Phase 3
Recruiting
1,264 enrolled